FIRST-LINE TREATMENT WITH CYTOTOXIC CHEMOTHERAPY VERSUS EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI) IN PATIENTS WITH EGFR WILD-TYPE ADVANCED LUNG ADENOCARCINOMA: Abstract ID – 211


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles